Real-World data reveals early use of prostate cancer drug in thousands of patients
NCT ID NCT07450157
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined medical records of over 6,400 prostate cancer patients who received a treatment called 177Lu-PSMA-617. Researchers wanted to understand the patients' characteristics, treatment patterns, and survival outcomes. The study did not test a new treatment but instead analyzed existing data to see how the drug was being used in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?